Special Conference - Paris 23-24 September, 2016

New perspectives in hepatitis C virus infection - The roadmap for cure

Description


 

Programme eBook now available


 

Download the mobile app (only for registered participants)

If you are registered for this event you should already have received an email with all the details and links enabling you to download the app.

Welcome Message

Dear Colleagues,

It is our pleasure to welcome you to the European Association for the Study of the Liver (EASL)-American Association for the Study of Liver Diseases (AASLD) Special Conference entitled 'NEW PERSPECTIVES IN HEPATITIS C VIRUS INFECTION - THE ROADMAP FOR CURE' to take place in Paris, France from September 23-24, 2016.

The recent and rapid advances in the treatment of hepatitis C have completely changed the scenario of this disease in the last months. It is not always easy to be updated in the field, due to the huge amount of data coming from a large number of published studies. Antiviral drugs that are still not approved in some countries are already classified as “old” and current treatment regimens may be replaced by new ones by the time the meeting takes place. The aim of this conference is to summarize the information available, as well as to provide a critical review and analysis of the best available (some unpublished data will be relevant) data. With this goal in mind, this meeting will give hepatologists, as well as other specialists interested in hepatitis C, the opportunity to catch up with the new advances in the field and be able to apply them in clinical practice. To reach this aim, an international panel of key experts and participants will actively interact to resolve pending issues and to highlight areas needing further analysis and investigation.

Central issues that will be addressed include:

  • Epidemiology of HCV in different areas of the world
  • Virology and pathogenesis
  • Natural history of the disease and impact of the new treatments on the long term consequences of chronic HCV infection
  • Assessment of the disease
  • Therapy, with special emphasis on difficult-to-treat populations or unsolved issues
  • HCV Eradication strategies We look forward to welcoming you to Paris for this exciting scientific event.

Sincerely,

The Scientific Committee

Who should attend?

Hepatologists, virologists, translational and clinical researchers, health professionals, young trainees.

Why attend?

  • 2 days of expertise and perspectives on Hepatitis C
  • 7 sessions covering the latest on Hepatitis C assessment and treatment
  • Gather and network with renowned specialists and leading experts.

Topics to be covered:

Epidemiology, Pathogenesis and Virology, HCV Assessment and Treatment, Special Patient Populations, Clinical and Translational Research.

CME Accreditation

This event is   being co-organized with the American Association for the Study of Liver Diseases (AASLD) and has been granted

CME Accreditation

EXHIBITION AND SPONSORSHIP PROSPECTUS